Profluent is at the forefront of biological innovation, leveraging AI to design proteins that revolutionize medicine, agriculture, and beyond. Our platform specializes in creating new biology through AI-authored proteins, enabling breakthroughs in various fields. By combining machine learning and biology, we partner to solve complex challenges, offering AI-generated solutions for therapeutics, industrial enzymes, and more.
我們正在追蹤 Profluent 的市場擴張
Profluent 的國際擴張與競爭對手的比較
Profluent你長條顯示所比較各公司之間的相對規模。
欄位5| 公司 | 市場 | 新市場 | 動能 | 活動 | 擴張評分 |
|---|---|---|---|---|---|
 Profluent你 | 0 | 0 | — | 0 | 0 |
目前並無招聘
註冊以追蹤此公司，並在發生變化時第一時間獲得提醒。
Profluent × Eli Lilly
已結束
Today we announced a landmark partnership with Eli Lilly and Company to use our AI models to design recombinases for genetic medicine—a collaboration valued at up to $2.25 billion before royalties.The goal: use Profluent's AI models to design recombinase editors capable of inserting long stretches of DNA at precise locations in the genome.Many genetic diseases involve hundreds of different mutations across patients–no single edit can address them all. Inserting a complete functional gene with a ...
已結束解鎖已驗證電郵與直撥電話
免費 · 無需信用卡
關於 Profluent 業務、市場及增長訊號的快速解答。
